SCHEMBL23633380

SCHEMBL23633380

CC(C)n1ncc2c(NS(=O)(=O)c3ccc(F)cc3)cc(-c3cccs3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.42
CCR2 P41597 1/20 0.41
TP53 P04637 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GHSR Q92847 2/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
GLO1 Q04760 1/20 0.37
POLB P06746 2/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
TSHR P16473 1/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 2/20 0.36
VDR P11473 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
PIK3CA P42336 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23633382 0.81 KDM4E (0.45) TP53SMN1; SMN2POLBKMT2AMEN1
SCHEMBL23633377 0.76 TP53 (0.50) TP53POLBKMT2AMEN1LMNA
SCHEMBL23633381 0.74 RXFP1 (0.39) TP53POLBKMT2AMEN1MAPT
SCHEMBL16783120 0.73 RXFP1 (0.54) TP53SMN1; SMN2POLBKMT2AMEN1
SCHEMBL16783143 0.73 RXFP1 (0.47) SMN1; SMN2POLBTSHRMAPTKDM4E
SCHEMBL18688479 0.73 CSNK2A1 (0.43) SMN1; SMN2POLBKMT2AMEN1MAPT
SCHEMBL16783148 0.73 RXFP1 (0.46) TP53SMN1; SMN2POLBMAPTKDM4E
SCHEMBL23633372 0.72 ALDH1A1 (0.45) SMN1; SMN2POLBKMT2AMEN1LMNA
SCHEMBL16783112 0.72 RXFP1 (0.48) TP53SMN1; SMN2POLBKMT2AMEN1
SCHEMBL23633371 0.70 RXFP1 (0.41) TP53SMN1; SMN2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787799-B2 Potent antiviral pyrazolopyridine compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-17 US disclosed
US-11787799-B2 Potent antiviral pyrazolopyridine compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-17 US disclosed
US-20220119384-A1 POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-04-21 US disclosed
US-11059817-B2 Potent antiviral pyrazolopyridine compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787799-B2 Potent antiviral pyrazolopyridine compounds MAVS, VRK1, VRK2 PPARG 2321/4885CCR2 1754/4885TP53 3148/4885
US-20220119384-A1 POTENT ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS MAVS, VRK1, VRK2 PPARG 2321/4885CCR2 1754/4885TP53 3148/4885
US-11059817-B2 Potent antiviral pyrazolopyridine compounds MAVS, VRK1, VRK2 PPARG 2321/4885CCR2 1754/4885TP53 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.